New drug shows promise for Tough-to-Treat myeloma in Long-Term study
NCT ID NCT06479954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the long-term safety and effectiveness of the drug elranatamab in people with relapsed and refractory multiple myeloma, a type of blood cancer that has not responded to other treatments. The study tracks side effects like cytokine release syndrome and nerve-related issues, as well as how well the drug controls the cancer. Only one patient is enrolled, so the results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab
What this could lead to
If successful, this study could confirm that elranatamab is a safe and effective long-term treatment option for people with hard-to-treat multiple myeloma.
What could go wrong
This is a very small study (only 1 participant) and is observational, so results may not apply to others. It focuses on safety monitoring, not proving a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan